Insulin Glulisine in Type 2 Diabetic Patients

Inclusion Criteria: * Diabetes Mellitus, Type 2 * 25 \< BMI \< 45 kg/m² * 7,5% \< HbA1c \< 9% * Treated with a basal insulin (NPH, Insulin Zinc, Insulin glargine or Insulin detemir), and at least 1g metformin daily, for more than 3 months Exclusion Criteria: * Type 1 diabetes mellitus * Treatment with OADs only * Treatment with thiazolidinediones, with exenatide or with pramlintide * Treatment with an insulin other than basal insulin (Premix, rapid insulin, fast-acting insulin analogue) * Active proliferative diabetic retinopathy, * Pregnancy (women of childbearing potential must have a negative pregnancy test at study entry and effective contraception) * Breast-feeding * History of hypersensitivity to the study drugs or to drugs with a similar chemical structure. * Treatment with systemic corticosteroids in the 3 months prior to study entry * Treatment with any investigational product in the 2 months prior to study entry * Previous treatment with insulin glulisine * Likelihood of requiring treatment during the study period with drugs not permitted by the clinical study protocol * Clinically relevant cardiovascular, hepatic, neurological, endocrine, or other major disease making implementation of the protocol or interpretation of the study results difficult * Impaired hepatic function * Impaired renal function * History of drug or alcohol abuse The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.